High-Dose Verapamil in Episodic and Chronic Cluster Headaches and Cardiac Adverse Events: Is It as Safe as We Think? by unknown
CASE REPORT
High-Dose Verapamil in Episodic and Chronic Cluster Headaches
and Cardiac Adverse Events: Is It as Safe as We Think?
Joachim Alexandre1,2,3,4 • Xavier Humbert5 • Marion Sassier1 •
Paul Milliez2,3,4 • Antoine Coquerel1,4,6 • Sophie Fedrizzi1
Published online: 28 August 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Cluster headache (CH) is a primary headache
disorder with relatively effective treatments. Although few
sufficiently controlled trials are available, verapamil is
recommended as the first-line prophylactic drug for CH by
the French Headache Society (with a low level of evidence,
level B) and by the EFNS (European Federation of Neu-
rological Societies, level A). Daily doses of more than
480 mg (and up to 1200 mg daily) are frequently used off-
label, while 360 mg daily is the only dosage to have
demonstrated its effectiveness in a double-blind trial
against placebo, and the usual label posology used by
cardiologists is 240 mg daily in hypertension. We report
the case of a 19-year-old man who was self-reported to our
cardiology consultation for dyspnea and asthenia for
18 months. His medical history consisted of CH crisis for
4 years treated by verapamil 720 mg/day for 18 months
with relatively good efficiency. His electrocardiogram
(ECG) showed a sinus bradycardia at 40 bpm with a first-
degree atrio-ventricular block. Evolution was favorable
after progressive verapamil discontinuation. Analysis per-
formed on the French Pharmacovigilance Database
between July 1, 2000 and December 1, 2014 found four
other cases of cardiac adverse events related to high-dose
verapamil used in CH prevention (two cases of syncope
with complete atrio-ventricular block with verapamil 1200
and 240 mg daily, respectively, one syncope related to sick
sinus syndrome with verapamil 360 mg daily, and one case
of sinus bradycardia with verapamil 720 mg daily).
Although available studies seem to demonstrate an appar-
ent good tolerance, this off-label practice should not be
considered as standard of care and requires strict cardiac
monitoring, as suggested by the Agence Nationale de
Se´curite´ du Me´dicament (ANSM) in a recent re-evaluation
of the benefit/risk ratio of high-dose verapamil used in CH
prevention.
Key Points
Despite a low level of recommendation, verapamil is
considered as the first-line prophylactic drug for
cluster headaches.
High-dose verapamil seems to be efficient in pain
management in selected and appropriate patients.
Serious cardiac adverse events could occur with
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Introduction
Cluster headache (CH) is a primary headache disorder
which is classified with similar conditions known as the
trigeminal autonomic cephalalgias in the International
Headache Society diagnostic criteria [1]. It is a rare but
very disabling condition. The disease has typical and
therefore easily recognizable clinical features and
specific criteria have been proposed. At least five
attacks fulfilling the following criteria are required for
diagnosis: severe or very severe unilateral orbital,
supraorbital and/or temporal pain lasting 15–180 min if
untreated; headache accompanied by at least one of the
following: ipsilateral conjunctival injection and/or
lacrimation, ipsilateral nasal congestion and/or rhinor-
rhea, ipsilateral eyelid edema, ipsilateral forehead and
facial sweating, ipsilateral miosis and/or ptosis; sense
of restlessness or agitation; frequency of the attacks
from once a day to eight per day; and headaches not
attributed to another disorder [1]. The intensity of the
attacks and the consequent disability are such that
patients require rapid diagnosis and appropriate treat-
ment. Effective options for both abortive and preven-
tive treatment are currently available. These options are
supported by updated international therapeutic guide-
lines [2].
Based on two old clinical trials [3, 4], verapamil is
recommended off-label [5] as the first-line prophylactic
drug for CH [2, 6]. The usual label posology recommended
is 240 mg daily (with a maximum of 360 mg daily) in
hypertension [5]. High-dose verapamil (480–600 mg daily)
may be used in cardiology practice in the rare short-cou-
pled variant of torsade de pointes syndrome, but it is usu-
ally given with the safety measure of an implantable
cardioverter defibrillator to prevent extreme bradycardia
[7]. In CH prevention, daily verapamil doses of more than
480 mg (and up to 1200 mg daily) are frequently used [8,
9]. This cure seems to involve 14.8 % of CH patients [10]
and is considered by neurologists as well tolerated and safe,
although verapamil 360 mg daily is the only dosage to
have demonstrated its effectiveness in a double-blind trial
against placebo [4].
CH pathophysiology and the mechanisms underlying
the effectiveness of verapamil in pain management are not
yet completely understood. One explanation for the use of
a higher verapamil dose in CH than in hypertension is that
at cardiologic doses, verapamil acts only as a calcium
channel blocker [11]. At a higher dose, verapamil could
also modulate central neuronal activity and affect
hypothalamic and noradrenergic functions and the opiate
system, which is particularly sensitive to high-dose ver-
apamil [12–16].
The aim of the present study was to discuss this off-label
use of high-dose verapamil in CH prevention, its security,
and the precautions inherent to this practice.
Case Report
We report the case of a 19-year-old man who was self-
reported to our cardiology consultation for dyspnea and
asthenia for 18 months. He was on work disability for
12 months because of a complete failure to realize any
effort. His medical history only consisted of very debili-
tating CHs for 4 years, which were treated with verapamil
720 mg/day for 18 months with good efficiency. He did
not have any past cardiologic history. There was no renal
function assay available. His other medications included
sumatriptan 6 mg and ketoprofene 100 mg (extended-re-
lease formulation). No electrocardiogram (ECG), either at
baseline condition or during clinical follow-up, was
available. His examination highlighted a cardiac frequency
at 40 bpm without any signs of heart failure. His ECG
showed a sinus bradycardia at 40 bpm with a first-degree
atrio-ventricular block (Fig. 1). There was no heart rate
increase despite the achievement of lower limb exercise for
several minutes, indicating a severe chronotropic incom-
petence that could explain the symptoms described by the
patient. Unfortunately, no verapamil blood measurement
was taken, but we can expect that it would have been above
the recommended therapeutic concentrations [17]. Vera-
pamil was gradually stopped. The patient was summoned
1 week later to undergo a new ECG. The latter showed the
recovery of a 70/min sinus rhythm without any atrio-ven-
tricular block and the complete disappearance of dyspnea
and asthenia. The patient was able to return to work
3 weeks after verapamil discontinuation. Regarding his
CHs, the verapamil was replaced by levetiracetam
1000 mg daily associated with sumatriptan 6 mg and
ketoprofene 100 mg (extended-release formulation), with a
favorable evolution. This case was notified to the Centre
Re´gional de Pharmacovigilance de Basse Normandie and
then registered in the French Pharmacovigilance Database.
The intrinsic causality assessment retained for verapamil in
our case was ‘very likely’ (C3S3 or I6) and the extrinsic
causality assessment (bibliographic causality assessment)
retained was ‘expected effect’ (B4) according to the French
method for causality assessment [3].
Review of the French Pharmacovigilance Database
Analysis performed on the French Pharmacovigilance
Database between July 1, 2000 and December 1, 2014
found four other cases of cardiac adverse events related to
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the use of high-dose verapamil in CH prevention. The
assessment of causality was performed according to the
French method for causality assessment [18]. Terms used
for this analysis included verapamil, cephalalgia, atrio-
ventricular block, bradycardia, syncope, cardiac disorders
and cardiac arrests. For the verapamil causality assessment,
only the cases with a ‘probable’ imputability were main-
tained. Two of them were cases of syncope with complete
atrio-ventricular block (verapamil 1200 mg daily in a
54-year-old man and 240 mg daily in a 53-year-old man,
respectively), one was a syncope related to sick sinus
syndrome (verapamil 360 mg daily associated with a
lithium intoxication in a 42-year-old man) and the last was
a case of sinus bradycardia (verapamil 720 mg daily in a
24-year-old man). None of these patients had a past car-
diologic history. There was no renal function assay avail-
able for these patients in either baseline condition (before
introducing verapamil) or during the cardiac adverse event.
Moreover, there was no blood verapamil measurement
performed for these patients.
Discussion
Although few sufficiently controlled trials are available [3,
4], verapamil is recommended off-label [5] as the first-line
prophylactic drug for CH by the French Headache Society
(with a low level of evidence, level B) [6] and by the EFNS
(European Federation of Neurological Societies, level A)
[2]. Frequently and without any double-blind trial against
placebo (the only dosage which has demonstrated its
effectiveness in a double-blind trial against placebo is
360 mg daily [4]), daily doses of verapamil[480 mg (and
up to 1200 mg daily) [8, 9] are used off-label and are
considered well tolerated and safe [4], while the usual label
posology recommended is 240 mg daily (with a maximum
of 360 mg daily) in hypertension [5]. Bussone et al. [3]
published in 1990 a study comparing verapamil 360 mg
daily for 8 weeks with lithium 900 mg daily in an Amer-
ican Academy of Neurology (AAN) Class II study. Thirty
patients with chronic CH participated in this crossover
study, and outcomes included the intensity, frequency, and
duration of attacks during the trial period. A total of 50 %
of patients in the verapamil group and 37 % of those in the
lithium group experienced an improvement in the headache
index, compared with the run-in period (p\ 0.01). Leone
et al. [4] studied verapamil at 360 mg daily versus placebo
for 2 weeks in 30 patients in an AAN Class III study. The
primary endpoint was the reduction in the frequency of the
attacks per week. Verapamil was found to be superior to
placebo. Patients taking verapamil experienced 0.6 attacks
per day, compared with 1.65 per day in the placebo group
(p\ 0.001). Only non-serious adverse effects were repor-
ted. Regarding these two studies, verapamil seems to be a
very effective treatment for pain management in CH.
Mechanisms of action of verapamil in CH are not
completely known. Neither is the pathogenesis of CH
understood. Initially, the hypothesis of a vascular genesis
was raised and therefore verapamil seemed to be interest-
ing in this context [19]. Now this hypothesis seems out-
dated and the exact mode of action of verapamil in relief of
pain management in CH is not clear. Verapamil is a
phenylalkylamine derivative which exerts its calcium
antagonist effect by interfering with the slow calcium
Fig. 1 Electrocardiogram made
during the patient examination
showing a sinus bradycardia at
40 bpm with a first-degree atrio-
ventricular block
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channels and thus modulates the calcium flux across cell
membranes [11]. Other observations indicated that calcium
antagonists act via a mechanism which is not only vascular.
Variations in regional cerebral blood flow and cere-
brovascular response to various stimuli were monitored in
groups of CH and migraine patients while undergoing
treatment with calcium antagonists [20, 21]. Results
showed that verapamil was more efficacious than other
calcium antagonists in treating CH, but induced minimal
changes in cerebral circulation which, in any event, were
less than those produced by other calcium antagonist drugs.
This poor correlation between vascular effects and clinical
efficacy suggests that the cerebral vascular bed may not be
the main site of action of verapamil in CH prophylaxis.
Other studies indicated that verapamil is able to modulate
central neuronal activity by several mechanisms: it may
influence muscarinic [12], serotoninergic [13], dopamin-
ergic, and noradrenergic receptors [14], it may also affect
hypothalamic and noradrenergic functions [15]. Of all the
cerebral transmitter systems, it is the opiate system which
is particularly sensitive to verapamil. When the drug is
administered in high doses, it is able to modify the anal-
gesic effect of morphine. It could also modulate the inhi-
bitory action that hypothalamic peptides exert on
morphine-induced analgesia and appears able to restore
correct function of the analgesic system in the presence of
an excess of these hypothalamic peptides—an action the
drug exerts after a short latency period [16].
However, despite the undeniable effectiveness of vera-
pamil in CH prevention, cardiac adverse events should not
be overlooked. In a recent study, Lanteri-Minet et al.
(Table 1) reviewed 29 patients with CH who were taking
720 mg or more of verapamil daily [10]. Eleven patients
(38 %) were found to have ECG abnormalities with
bradycardia (n = 7), first-degree atrio-ventricular block
(n = 2), second-degree atrio-ventricular block (n = 1) and
third-degree atrio-ventricular block (n = 1) [10]. ECG
changes have been considered a cardiac serious adverse
event in four patients (14 %). Authors did not find any
significant predictive factor except verapamil dose. Indeed,
cardiac serious adverse events concerned patients using an
average very high verapamil daily dose of 990 ± 315 mg.
Cardiac serious adverse event onset could be delayed (three
patients presented cardiac serious adverse events at 72, 71,
and 24 months after the very high dose was achieved).
Cohen et al. [22] audited the ECG abnormalities in 217
patients with CH on verapamil therapy at a mean dose of
512 mg daily (Table 1). Among the 217 patients, ECG was
only available in 128 patients (59 %). Thirteen patients
presented first-degree atrio-ventricular block, four patients
had junctional rhythm, and one had second-degree atrio-
ventricular block. Bradycardia\60 bpm was noticed in 39
patients. In eight patients, the PR interval was lengthened,
but not to[0.2 s. Authors concluded that high-dose vera-
pamil was linked to frequent severe cardiac outcomes
(estimated to one in five) and that a substantial number of
patients did not have ECG monitoring as recommended.
This ECG monitoring seems to be particularly important in
that significant ECG abnormalities can develop with time,
even on a stable dose. Following publications regarding
ECG abnormalities, the recommendations for titration of
verapamil have evolved. A starting dose of verapamil
80 mg three times a day, increasing by 80 mg each week
until a dose of 480 mg daily is reached has recently been
proposed. Beyond 480 mg, an increase in the daily dose of
80 mg every 15 days is recommended in order to have a
consistent decline on increasing doses [23]. Other teams
offer faster titration in patients with more than two seizures
a day, starting at 120 mg twice daily and increasing the
daily dose by 120 mg every 48 h [24].
All these results show that high-dose verapamil used in
CH may not be as well tolerated as suggested and serious
cardiac adverse events could occur in practice. Considering
the frequent use of high daily doses, cardiac safety
assessment with systematic ECG monitoring is essential in
the management of CH patients treated with verapamil,
particularly in elderly patients who are at higher risk of
cardiac conduction disorders [25]. In daily practice, this
Table 1 Adverse cardiac events with high-dose verapamil use
Lanteri-Minet et al. [10] Cohen et al. [22]
Number of patients 29 217
Average verapamil dosage, mg/day 877 512
Number of ECG available (%) 29 (100 %) 128 (59 %)
Number of ECG abnormalities (%) 15 (52 %) 57 (44 %)
Type of abnormalities (%) Bradycardia: 7 (24 %)
First-degree AV block: 2 (7 %)
Second-degree AV block: 1 (3 %)
Third-degree AV block: 1 (3 %)
Junctional rhythm: 4 (14 %)
Bradycardia: 39 (30 %)
First-degree AV block: 13 (10 %)
Second-degree AV block: 1 (1 %)
Third-degree AV block: 0 (0 %)
Junctional rhythm: 4 (3 %)
AV atrio-ventricular, ECG electrocardiogram
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recommendation seems not to be systematically applied
[22]. Our work highlights the need for a systematic ECG
before verapamil initiation in order to screen absolute (such
as high-grade atrio-ventricular block or sick sinus syn-
drome in patients without a permanent pacemaker) and
relative (such as first-degree atrio-ventricular block) vera-
pamil contraindications and an annual ECG follow-up
along with a cardiologist visit because of the risk of
delayed cardiac serious adverse events. It could also seem
reasonable to perform at least one trans-thoracic echocar-
diography before verapamil initiation (particularly for high
doses) in order to assess the left ventricular ejection frac-
tion. In the setting of ‘cardiologic’ verapamil use, the
European Society of Cardiology guidelines [26] recom-
mend an echography before verapamil initiation. In fact,
verapamil is a potent negative inotropic agent that could
induce cardiogenic shock in case of systolic heart failure
[26] or in case of voluntary poisoning [27]. These recom-
mendations seem all the more important to observe if the
patient is old or has significant cardiovascular comorbidi-
ties. Indeed, given literature data [10, 25] and the French
Pharmacovigilance Database, patients presenting with
serious cardiac adverse events seem to be the oldest.
Verapamil is metabolized by cytochrome P450 (CYP)
3A4 to inactive and to active metabolites [28], the most
important being norverapamil, which is less cardiotoxic than
its parent compound [29]. Therefore, CYP 3A4 inducers and
inhibitors are likely to result in decreased and increased
plasma levels of verapamil, respectively [30–32]. Co-med-
ication with other drugs indicated in CH such as triptans,
prednisolone or ergotamine, which are also metabolized by
CYP 3A4, could induce a drug–drug interaction with vera-
pamil [33, 34]. Verapamil is also a probe inhibitor of
transporter P-glycoprotein (P-gp). P-gp is located throughout
the body, including the gastrointestinal tract, where it can
directly limit oral drug absorption [35]. Previous studies
have demonstrated that short-term usual-dose verapamil
inhibits intestinal P-gp, whereas long-term usual-dose
administration may induce P-gp expression [36]. Co-medi-
cation with prednisolone, which is also transported by P-gp,
may therefore induce a drug–drug interaction with vera-
pamil [37]. It is important to note that high-dose verapamil
impact on P-gp and CYP 3A4 expression has never been
studied but we can suppose a major impact on co-medica-
tion oral bioavailability. Note that an ECG will be required
in case of even temporary co-medication with CYP 3A4 or
P-gp inducers/inhibitors. Another important co-medication
is the lithium coprescription. Indeed, lithium is an available
CH treatment supported by international therapeutic guide-
lines [2], but lithium is also a well known medication which
may induce bradycardia, sick-sinus syndrome and atrio-
ventricular block, especially in cases of intoxication [38].
Finally, off-label use of a drug is still a high-risk practice.
However, in this case, the use of high-dose verapamil is an
especially high-risk practice as it exposes patients to serious
cardiac side effects (ECG abnormalities) and to the risk of
major drug–drug interactions.
Finally, it is unfortunate that no blood drug confirmatory
assay was achieved in clinical studies and in cases reported
in the French Pharmacovigilance Database. Therapeutic
plasma levels of verapamil are 0.20–0.35 lg/mL, with
toxic concentration at values exceeding 9 lg/mL [17]. A
confirmatory assay would allow the link between high-dose
verapamil and serious cardiac adverse events occurrence to
be tested, it could help clinicians to avoid ‘toxic’ doses and
it could also inform the verapamil dosage escalation
without reaching the toxicity threshold.
Our recommendations are consistent with those pub-
lished recently by the Agence Nationale de Se´curite´ du
Me´dicament (ANSM), which recently re-evaluated the
benefit/risk ratio of high posology verapamil used in CH
prevention [39]. This commission gave a favorable opinion
to set up a temporary recommended use for verapamil
administered orally in CH prophylactic treatment depend-
ing on strict adherence to the procedures for monitoring
listed in the temporary recommended use protocol. The
commission also recommends that an ECG be performed
and a cardiologist’s opinion sought before verapamil ini-
tiation and new ECGs performed when adding or stopping
any medication which could affect verapamil plasma
concentrations as part of a drug–drug interaction. The
French Headache Society guidelines [6] also recently
published official guidelines regarding the verapamil
titration protocol and the absolute necessity of strict ECG
monitoring. The French Headache Society guidelines seem
also more reluctant than the EFNS guidelines regarding the
level of recommendation of verapamil used in CH [2, 6].
Study Limitations
Although this study highlights interesting elements, it
remains a case study with all the limitations that entails.
Moreover, the French Pharmacovigilance Database prob-
ably underestimates the real number of serious cardiac
adverse events due to high-dose verapamil and it is there-
fore difficult to know the real incidence of these side
effects in real life.
Conclusions
Safety issues remain rightfully prominent with high-dose
verapamil in CH [22]. Serious cardiac adverse events,
although a very infrequent direct event from high-dose
verapamil, nevertheless remain a risk as significant ECG
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abnormalities can develop with time even on a stable dose
[22]. However, the benefits of using verapamil in CH (if
necessary at doses exceeding those used by cardiologists in
hypertension) for pain management and prevention in
selected and appropriate patients seem to be favorable [3, 4].
The above-described case report and the French Pharma-
covigilance Database review show that care must be taken
when administering off-label high-dose verapamil in CH.
This work is consistent with a recent report published by
ANSM [39] and the French Headache Society guidelines [6]
granting a temporary recommended use for verapamil
administered orally in the prophylactic treatment of CH.
These recommendations were determined with strict respect
of the procedures for monitoring listed in the temporary
recommended use protocol, including strict cardiac moni-
toring. Indeed, serious cardiac adverse events may occur,
particularly in elderly patients. Caution must be paid to
patient selection and we recommend a cardiologist visit with
ECG and echocardiography before any treatment initiation,
and strict and regular ECG monitoring all throughout the
treatment. Attention must be paid to the patient’s co-medi-
cation when using verapamil because of the risk of drug–
drug interaction and, even more so, because high doses have
never been studied in this context. Finally, although high-
dose verapamil use in CH prevention is recommended with
caution by some clinical studies and expert opinion, this
practice remains to date off-label. It seems essential to
respect the cardiac monitoring recommendations.
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